BioSpace News Archive

PLT Health Solutions, Inc announced the publication of a clinical study on its Boswellia serrata -based AprèsFlex ® 5-Day Joint Support ingredient that provides further evidence of its ability to support joint health and function with statistically significant improvements in pain scores and biomarkers starting at only five days from initial consumption.

Daewoong Pharmaceutical’s new medication DWN12088 has been fast-tracked by the American FDA, the first time a Korean pharma company has been awarded this status.

G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the second quarter of 2022 on Wednesday, August 3, 2022, at 8:30 a.m. ET.

Zynex, Inc . (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that the company will report second quarter 2022 financial results on Thursday, July 28, 2022.

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), today announces that the US Food and Drug Administration (FDA), has announced a forthcoming public advisory meeting of the Oncologic Drugs Advisory Committee (ODAC), on September 22, 2022, to discuss the benefit/risk of Pepaxto® (melphalan flufenamide).

Halberd Corporation (OTC Pink: HALB) announced the formation of Halberd Cancer Therapeutics, LTD, as a wholly owned subsidiary.

Specialty cancer diagnostics company Precipio, Inc., announced that it has entered into an agreement with Fisher Healthcare, a part of Thermo Fisher Scientific to distribute its proprietary HemeScreen assays to its customers.

Forecast to 2030,’ thoroughly examines the Delirium industry to provide essential data & information for the targeted readers.

Scientists at deCODE genetics a subsidiary of Amgen together with collaborators from Denmark report on the whole genome sequences of 150 thousand participants in the UK biobank in a paper published in the journal Nature.

Forecast to 2030,’ thoroughly examines the Hypoxia industry to provide essential data & information for the targeted readers.